Korean startup HME Square, which is developing a non-invasive blood glucose monitor, has received a pre-Series A investment of 4 billion won from LB Investment and KB Investment.

Following its seed investment from POSTECH Holdings, HME Square concentrated on research and development, mainly through government-supported projects. Now, in the final stages of R&D, the company has secured momentum for the clinical trials and medical device approval of its flagship product, a non-invasive blood glucose monitor.

HME Square owns technology for non-invasive blood glucose monitoring based on photoacoustic methods. The company is in the process of developing GlucoSOUND, a non-invasive blood glucose monitor. This product aims to overcome the limitations of existing monitors, such as those requiring lancets or needles, by enabling accurate blood glucose measurements without the need for blood collection or needle use.

With the recent funding, the company plans to further refine its technology and products by recruiting top talent. Additionally, HME Square is committed to becoming the first to obtain medical device approval for a non-invasive blood glucose monitor through comprehensive domestic and international clinical trials.

HME Square was founded in 2020 by Yoonho Kang, a Ph.D. graduate from Seoul National University with 30 years of experience in semiconductor research and development. The company was also selected for the fourth group of the IBK Innovation Center Daejeon, a startup incubation program operated by the IBK.